The 15th World ADC London was held on March 3-6, 2025. Antibody-drug conjugates (ADCs) are at the forefront of biopharma, driven by major approvals and industry investments expanding their therapeutic reach. Celebrating its 15th year, World ADC London unites experts across discovery, manufacturing, and strategy to advance ADC development and maximize their therapeutic potential.
→ Biointron’s Highlighted Points:
1. Blockbuster ADCs Pushing the Boundary: Showcasing the ADCs Reshaping Standard of Care Oncology Treatments into Wider Patient Populations
Examining Enhertu’s historic HER2-positive solid tumor approval, this discussion explored DESTINY trial data, ongoing research in HER2 ultralow populations, and insights from DB06 to assess impact, success factors, and challenges in expanding ADC therapy. (Daiichi Sankyo)
Phase II & III readouts of Luvelta targeting FRα in recurrent ovarian cancer, endometrial cancer, and AML, is discussed, while exploring future ADC innovations like dual payload and immune-activating payload conjugates. (Sutro Biopharma)
2. Establishing Confidence in the Clinic: Comprehensively Understanding ADC Clinical Performance to Maximise Therapeutic Index
The journey from IND to long-term commercial supply for bioconjugates, is discussed, highlighting early-stage program support, development studies, and updates on conjugation and fill/finish capabilities. (BSP Pharmaceuticals)
This session highlighted the impact of ADC design philosophy on topoisomerase ADCs, preclinical readouts, design components in performance, and forecasting its clinical trial validation. (Zymeworks)
3. Evaluating Novel ADC Formats & Payloads in the Clinic – How Do They Perform Against Classical ADCs?
The clinical performance of Zelenectide Pevedotin and BT5528 was compared, and safety profiles and toxicity against classical ADCs, while analyzing preclinical and clinical differences through PKPD analysis to highlight the advantages of Bicycle Toxin Conjugates. (Bicycle Therapeutics)
ADCs have superior therapeutic potential, with expansion into bispecific and dual warhead ADCs, and groundbreaking mRNA exon skipping for Duchenne muscular dystrophy. (Synnafix)
4. Process & Analytical Development
The clinical profile and Phase I data of HDP-101 targeting BCMA in myeloma, explores 17p deletion as a biomarker for amanitin payload ADCs, and discusses future directions in precision medicine ADC development. (Heidelberg Pharma)
One session evaluates the need for biomarker and patient selection tools in the ADC field, discussing methodologies like machine learning and digital pathology for ADC target expression, addressing challenges in patient population selection, and predicting future trends in precision medicine ADC development.
Thank you for visiting us at our booth at World ADC 2025 in London to learn about our services! We had a great time connecting with you and understanding how we can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com!
